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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Several studies have already reported that serum potassium (SK) corre-
lated inversely with adverse events among patients with preexisting cardiovascular disease and
impaired renal function; less is known about the prognostic value of SK at the normal range in
community-based elderly individuals. This study aimed to examine whether low normal SK
value was associated with cardiovascular and all-cause mortalities in elderly people.
Methods: A prospective study was conducted using two independent elderly Taiwanese
community cohorts that included 2065 individuals with relatively normal SK values
(2.8e5.6 mmol/L). The participants were grouped as follows: low (2.8e3.4 mmol/L), low-
normal SK (3.5e3.8 mmol/L), normal (3.9e4.4 mmol/L), and high-normal SK (4.5e5.6 mmol/L).
Proportional hazards model was applied to compare the association between SK concentration
groups and mortality.
Results: The relationship between baseline SK and all-cause and cardiovascular mortality
was U-shaped, with the lowest mortality rates observed in patients with SK levels of
3.9e4.4mmol/L. The low-normal SK group had significantly higher risks of all-cause (hazard ratio,
1.3; 95% confidence interval, 1.0e1.6) and cardiovascular mortality (hazard ratio, 1.6; 95% confi-
dence interval, 1.1e2.3) than the normal SK group. The high-normal SK group had higher but
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518 Y.-H. Lai et al.Conclusion: Our findings suggest that low-normal SK may be used as a marker of poor survival for
elderly outpatient cares.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Potassium homeostasis is critical to avoid adverse conse-
quences in patients with cardiovascular disease (CVD).
Normally, serum potassium (SK) level is tightly maintained
between 3.5 mmol/L and 5.5 mmol/L,1e3 and departure
from normal may cause severe consequences including
muscular weakness,4 paresthesia, cardiac arrhythmias, and
sudden death.5 Although several studies have already re-
ported that SK correlated inversely with adverse events
among patients with preexisting CVD and impaired renal
function,6,7 less is known about the prognostic value of SK
within the normal range and in general populations.
Walsh et al8 have reported that there is no significant
association between the SK level and adverse events among
young participants. However, Wannamethee et al9 showed
that it is not the “low potassium,” but the “raised potas-
sium” that was associated with higher cardiovascular and
all-cause mortality in middle-aged men, suggesting the
questionable role of SK in determining future adverse
events in the general population. By contrast, an earlier
study has reported a negative association between potas-
sium intake and risk of cerebrovascular events.10,11 Our
previous study showed that switching to potassium-
enriched salt is beneficial for life span prolongation and
CVD mortality and medical cost reduction in elderly men.
The aforementioned suggests that the prognostic value of
SK remains undetermined especially for the elderly.12
However, there is a lack of adequately powered studies in
the general elderly population, and this information is
extremely important for geriatric care; to address this
critical knowledge gap, we took advantage of two
community-based elderly cohorts to examine whether the
SK value within the normal range is associated with car-
diovascular and all-cause mortalities in elderly people.Participants, design, and methods
Study population
We performed the present study using two independent
Taiwanese community-based elderly cohorts. One is the
Elderly Nutrition and Health Survey in Taiwan (Elderly
NAHSIT) performed during 1999e2000, which has complete
information on 1400 participants.13 The other is a cohort
from a veteran retirement home (VRH) study, which has
complete data on 665 veterans. The detailed description
and design of the Elderly NAHSIT and the VRH study can be
found elsewhere.12,13 The VRH study was approved by re-
viewers of the National Science Council, and Elderly NAHSIT
was approved by the Ethics Committees of the National
Health Research Institutes and Academia Sinica in Taiwan.Baseline measurements
Fasting venous blood samples were collected for a battery
of biochemical analyses. Serum levels of potassium, sodium,
glucose, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), total cholesterol,
triglycerides, uric acid, and creatinine were measured using
a COBAS INTEGRA 800 (Roche, Mannheim, Germany) for the
VRH study and for the Elderly NAHSIT. The body weight and
height of the elderly were measured, following the same
protocol. The body mass index (BMI) was calculated by
dividing body weight (kg) by height square (m2). The esti-
mated glomerular filtration rate (eGFR) was calculated
using the abbreviated Modification of Diet in Renal Disease
Study equation.14 Structured questionnaires covering soci-
odemographics and medical histories were administered by
trained interviewers. Medical histories included hyperten-
sion medication, diabetes mellitus medication, and self-
reported doctor-diagnosed heart disease, kidney disease,
and stroke. Three blood pressure measurements were ob-
tained by trained technicians, and the last two measure-
ments were averaged and used for statistical analysis. The
measurement was taken with a calibrated mercury sphyg-
momanometer and cuffs of the appropriate size, with the
participant seated for 5e10 minutes.
In order to examine the prognostic value of low-normal
and high-normal SK, individuals with SK values between
2.8 mmol/L and 5.6 mmol/L were included in this study. As
there are no standardized cut-points, in this study the
participants were categorized into low (2.8e3.4 mmol/L),
low-normal (3.5e3.8 mmol/L), normal (3.9e4.4 mmol/L),
and high-normal (4.4e5.6 mmol/L), considering this should
provide a sufficient number of people in the low-normal
and high-normal groups and also taking into consideration
the cut-points of several previous studies, in which low SK
has been defined by 3.70 mmol/L,15 3.90 mmol/L,9,16,17
or 4.00 mmol/L8,18 and high SK by 4.00 mmol/L,16,17
4.50 mmol/L,15 5.20,8,9 or 5.50 mmol/L.18
Follow-up and outcome measurements
Baseline information was linked to the National Death
Registry database for an 8-year follow-up. The govern-
ment’s confidentiality regulations were followed in the
linkage process. The personal identification numbers were
encrypted, and thus no privacy data from the study in-
dividuals could be identified. All-cause and cardiovascular-
related deaths were coded with the International Classifi-
cation of Diseases, ninth revision (ICD-9). Cardiovascular-
related deaths include those caused by diabetes (ICD-
9:250), hypertension (ICD-9: 401e405), ischemic heart dis-
ease (ICD-9: 410e414), heart failure (ICD-9: 428), and
stroke (ICD-9: 430e438).12
Table 1 Baseline characteristics by serum potassium (SK) groups.
Characteristics Low SK
(2.8e3.4 mmol/L)
Low-normal SK
(3.5e3.8 mmol/L)
Normal SK
(3.9e4.4 mmol/L)
High-normal SK
(4.5e5.6 mmol/L)
p for trenda
n (%) 51 (2.5) 252 (12.2) 1152 (55.8) 610 (29.5)
Male 31 (60.8) 144 (57.1) 718 (62.3) 484 (79.3) <0.001
Age, y 71.9  5.8 73.0  6.3 72.4  5.7 73.6  6.1 0.005
Body mass index, kg/m2 25.0  4.4 23.2  3.7 23.8  3.5 23.6  0.5 0.640
Hypertension 30 (58.8) 95 (37.7) 413 (35.9) 255 (41.8) 0.914
Diabetes 7 (13.7) 21 (8.3) 138 (12.0) 87 (14.3) 0.051
Self-report heart disease 11 (21.6) 48 (19.1) 235 (20.4) 170 (27.9) 0.002
Self-report kidney disease 6 (11.8) 8 (3.2) 59 (5.1) 54 (8.9) 0.018
Self-report stroke 6 (11.8) 18 (7.1) 76 (6.6) 65 (10.7) 0.100
Serum LDL-C, mg/mL 115.0  27.4 116.4  41.3 123.4  35.6 117.9  35.4 0.972
Serum HDL-C, mg/mL 53.0  16.5 52.4  15.8 51.9  15.2 50.6  15.9 0.050
Serum cholesterol, mg/mL 195.2  29.8 194.4  39.9 200.4  39.3 194.7  40.9 0.543
Serum triglyceride, mg/mL 133.0  100.4 132.9  104.5 128.2  110.2 122.5  81.9 0.134
Serum glucose, mg/mL 116.3  36.9 114.0  43.8 111.6  40.2 110.6  44.4 0.196
Serum uric acid, mg/mL 7.25  2.10 6.53  2.01 6.44  1.77 6.57  1.75 0.464
Serum creatinine, mg/mL 1.06  0.29 0.97  0.29 1.01  0.28 1.21  0.54 <0.001
Serum sodium, mmol/L 141.4  3.3 141.1  3.9 141.3  2.8 142.1  3.9 <0.001
Systolic blood pressure, mmHg 143.0  22.5 139.1  21.9 136.9  20.5 140.4  21.6 0.397
Diastolic blood pressure, mmHg 78.7  11.2 76.4  12.0 76.1  11.2 75.0  12.1 0.011
eGFR (mL/min/1.73 m2) 69.8  17.4 76.3  18.3 73.8  17.9 65.3  18.3 <0.001
eGFR (mL/min/1.73 m2) þ90 5 (9.8) 38 (15.1) 125 (10.8) 32 (5.3) <0.001b
60e89 32 (62.7) 174 (69.0) 799 (69.4) 354 (58.0)
30e59 13 (25.5) 38 (15.1) 219 (19.0) 205 (33.6)
<30 1 (2.0) 2 (0.8) 9 (0.8) 19 (3.1)
Data are presented as n (%) or mean  SD.
eGFR Z estimated glomerular filtration rate; HDL-C Z high-density lipoprotein cholesterol; LDL-C Z low-density lipoprotein cholesterol.
a p value was tested with the general linear model for continuous variables and logistic regression model for categorical variables for all
the variables in the table except the last item.
b p value was tested with Chi-square test.
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Table 2 Baseline characteristics by serum potassium status for the Elderly NAHSIT and the veteran retirement home (VRH) study.
Characteristics Elderly NAHSIT p for
trenda
VRH study p for
trendaLow Low-normal Normal High-normal Low Low-normal Normal High-normal
serum potassium concentration (mmol/L) serum potassium concentration (mmol/L)
2.8e3.4 3.5e3.8 3.9e4.4 4.5e5.6 2.8e3.4 3.5e3.8 3.9e4.4 4.5e5.6
n (%) 42 (3.0) 201 (14.4) 882 (63.0) 275 (19.6) 9 (1.4) 51 (7.7) 270 (40.6) 335 (50.4)
Male 22 (52.4) 93 (46.3) 448 (50.8) 149 (54.2) 0.179 9 (100.0) 51 (100.0) 270 (100.0) 335 (100.0) d
Age, y 70.7  5.3 71.8  5.3 71.7  5.3 72.5  5.4 0.038 77.4  5.0 77.7  7.7 74.6  6.4 74.5  6.5 0.011
Body mass index,
kg/m2
25.4  4.5 23.3  3.8 23.8  3.6 23.3  3.6 0.052 23.1  3.8 22.4  3.1 23.7  3.3 23.8  3.4 0.032
Hypertension, 23 (54.8) 74 (36.8) 284 (32.2) 110 (40.0) 0.591 7 (77.8) 21 (41.2) 129 (47.8) 145 (43.3) 0.223
Diabetes 7 (16.7) 17 (8.5) 93 (10.5) 48 (17.5) 0.027 0 (0.0) 4 (7.8) 45 (16.7) 39 (11.6) 0.974
Self-report heart
disease
6 (14.3) 33 (16.4) 154 (17.5) 63 (22.9) 0.044 5 (55.6) 15 (29.4) 81 (30.0) 107 (31.9) 0.884
Self-report kidney
disease,
5 (11.9) 5 (2.5) 20 (2.3) 14 (5.1) 0.877 1 (11.1) 3 (5.9) 39 (14.4) 40 (11.9) 0.759
Self-report stroke 5 (11.9) 11 (5.5) 33 (3.7) 12 (4.4) 0.099 1 (11.1) 7 (13.7) 43 (15.9) 53 (15.8) 0.710
Serum LDL-C, mg/mL 115.3  26.8 119.1  36.5 125.9  33.6 123.6  36.7 0.066 113.9  31.9 105.7  55.3 115.2  40.3 113.2  33.7 0.653
Serum HDL-C, mg/mL 55.8  16.0 52.7  14.4 53.3  15.2 52.9  14.8 0.588 39.7  12.4 51.3  20.6 47.4  1 4.3 48.7  16.5 0.613
Serum cholesterol,
mg/mL
199.7  26.7 200.7  37.9 204.6  38.8 203.8  43.6 0.332 174.4  35.9 169.7  38.5 186.5  37.8 187.3  37.0 0.016
Serum triglyceride,
mg/mL
142.9  107.7 144.0  111.6 127.1  88.3 136.4  93.3 0.367 86.8  24.6 89.1  50.4 132.0  162.6 111.2  69.4 0.943
Serum glucose, mg/mL 115.8  35.4 116.4  46.5 113.2  38.7 120.0  51.5 0.346 118.6  45.4 104.4  28.8 106.3  44.3 102.8  35.9 0.233
Serum uric acid,
mg/mL
7.42  2.13 6.63  1.97 6.55  1.77 6.85  1.85 0.917 6.44  1.83 6.14  2.12 6.10  1.74 6.34  1.63 0.209
Serum creatinine,
mg/mL
1.05  0.31 0.93  0.29 0.96  0.26 1.15  0.50 <0.001 1.13  0.20 1.14  0.26 1.18  0.28 1.27  0.57 0.006
Serum sodium, mmol/L 141.2  2.8 141.2  2.1 140.8  2.0 140.3  2.6 <0.001 142.1  5.2 141.0  7.7 142.9  4.0 143.6  4.1 <0.001
Systolic blood
pressure, mmHg
141.6  22.7 138.1  21.6 135.7  20.4 138.0  21.6 0.525 149.7  21.4 143.4  22.9 140.6  20.5 142.4  21.5 0.936
Diastolic blood
pressure, mmHg
78.9  11.5 76.7  11.8 76.4  10.9 74.6  11.2 0.007 77.6  10.6 75.2  12.8 75.2  12.1 75.3  12.8 0.884
eGFR(mL/min/1.73 m2) 70.0  18.0 77.7  18.0 75.4  17.7 66.3  20.8 <0.001 69.1  15.0 70.6  18.6 68.4  17.2 64.5  15.9 0.001
eGFR (mL/min/1.73 m2) þ90 4 (9.5) 35 (17.4) 108 (12.2) 21 (7.6) <0.001b 1 (11.1) 3 (5.9) 17 (6.3) 11 (3.3) 0.532b
60e89 26 (61.9) 140 (69.7) 632 (71.7) 151 (54.9) 6 (66.7) 34 (66.7) 167 (61.9) 203 (60.6)
30e59 11 (26.2) 24 (11.9) 135 (15.3) 91 (33.1) 2 (22.2) 14 (27.5) 84 (31.1) 114 (34.0)
<30 1 (2.4) 2 (1.0) 7 (0.8) 12 (4.4) 0 (0.0) 0 (0.0) 2 (0.7) 7 (2.1)
Data are presented as n (%) or mean  SD.
eGFR Z estimated glomerular filtration rate; HDL-C Z high-density lipoprotein cholesterol; LDL-C Z low-density lipoprotein cholesterol.
a p value was tested with the general linear model for continuous variables and logistic regression model for categorical variables for all
the variables in the table except the last item.
b p value was tested with Chi-square test.
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The baseline characteristics of the study participants were
profiled and compared between SK groups. A general linear
model was carried out to test the trends for continuous vari-
ables, and a logistic regression model was conducted to test
that for the proportions of the categorical variables among
potassium groups. Follow-up time was calculated from the
blood sampling date to the date of death or the end of the
follow-up period. Survival probability was estimated and
survival curves for the low and low-normal SK groups were
plotted and compared to the mid-normal by using the
KaplaneMeier estimate, and the log-rank testwas used to test
the equality among survival curves. The Cox proportional-
hazard model (PH model) was used to calculate age and
multivariable-adjusted hazard ratios (HRs) across SK groups
for all-cause and cardiovascular mortalities. All models were
adjusted for age, body mass index; serum LDL-C, HDL-C,
cholesterol, triglyceride, glucose, uric acid, creatinine, and
sodium; systolic blood pressure, diastolic blood pressure,
hypertension, and diabetes medication; and presence of self-
reported heart disease, kidney disease, and stroke. Sex was
additionally adjusted in the Elderly NAHSIT. And in combined
analysis, study effect was controlled. SAS version 9.3 (SAS
Inc., Cary, NC, USA) was used for data analyses.Results
Study sample and baseline characteristics
The baseline characteristics of the 2065 study participants
by strata of low, low-normal, normal, and high-normal SK
levels are shown in Table 1, and similar study-specificFigure 1 Distribution of baseline serum potassium levels and
comparing mortality of low (2.8e3.4 mmol/L), low-normal (3.5e3.8
normal (3.9e4.4 mmol/L) SK group, estimated with Cox PH model.participants’ characteristics are given in Table 2. In gen-
eral (Table 1), the higher the SK concentration, the higher
the mean age, serum creatinine, and sodium, and the
percentages of male, diabetes patients, and self-reported
history of heart and kidney disease; but lower mean dia-
stolic blood pressure and HDL-C according to the trend test.
That is, people in the low-normal SK group were younger,
with better kidney function and better lipid profiles, and
had a lower percentage of chronic disease history. The
baseline comparative results on eGFR, serum sodium, and
creatinine were consistent between the two cohorts.
However, the trends with SK were not the same for two
cohorts for age, body mass index, diabetes, and some other
disease histories.
SK level and mortality
As shown in Fig. 1, the relationship between baseline SK and
all-cause or cardiovascular mortality was U-shaped, with the
lowest mortality rates observed in patients with potassium
levels of 3.9e4.4 mmol/L. Significant differences were
observed between normal SK groups and the two low SK
groups, although significance was not seen with the low SK
group for CVD. The survival curves for all-cause and cardio-
vascular mortalities were plotted for the low, low-normal,
and normal K groups using the KaplaneMeier estimates
(Fig. 2). There were significant differences among the three
curves for all-cause mortality (p < 0.001; Fig. 2A) and for
cardiovascularmortality (pZ 0.017; Fig. 2B). TheHRs for all-
cause and cardiovascular mortalities comparing the low, the
low-normal, and high-normal SK groups with the normal
group were estimated using the Cox PH model and are pre-
sented in Table 3. Age and multiple risk factors of cardio-
vascular mortality were adjusted in these models. In themortality rates by serum potassium groups. a Hazard ratios
mmol/L), and high-normal (4.5e5.6 mmol/L) SK groups to the
SK Z serum potassium.
Figure 2 Survival curves for low, low-normal, and normal serum potassium groups. (a) All-cause mortality. (b) CVD mortality.
a Survival probability was estimated, and survival curve is plotted for each serum potassium level using the KaplaneMeier estimate.
CVD Z cardiovascular disease.
522 Y.-H. Lai et al.combined analysis, the low (1.8, 1.3e2.7) and the low-
normal (1.3, 1.0e1.6) SK groups had greater risks for all-
cause mortality, and so had those for CVD. However, for
CVD, statistical significance was seen only in the low-normal
SK group. In the Elderly NAHSIT and in the VRH study, the
association between SK level and mortality is similar to that
in the combined analysis, except that statistical significance
was not reached in the VRH study for all-cause and cardio-
vascular mortalities (Table 4).Discussion
Abnormal SK values were known to dominantly affect the
cardiovascular system and have been implicated in many
aspects of CVD including cardiac arrhythmia, hypertension,
stroke, myocardial ischemia, and sudden cardiac death.19
The U-shaped association between serum concentrations
of potassium and cardiovascular death as well as all-cause
death has been clearly demonstrated among patients with
acute myocardial infarction and renal failure.20,21 The
highest mortality rate observed among those with lower
potassium concentration indicated the importance ofavoiding hypokalemia for patients with cardiovascular risk.
Our current study for the first time demonstrated that low-
normal SK level is still associated with higher risks of car-
diovascular death and all-cause death among community-
dwelling elderly people, which further highlights the
importance of keeping the SK level higher than the lower
bound of the normal range even in community-dwelling
elderly.
Low SK has been associated with an increased risk of
adverse events in patients with preexisting CVD and renal
failure.21e24 It may cause cellular hyperpolarity, increase
resting membrane potential, and increase automaticity and
excitability, leading to occurrence of cardiac arrhythmia
and sudden cardiac death.25e27 Hulting22 showed an inverse
relationship between SK and ventricular fibrillation inci-
dence. An almost five-fold increase in ventricular fibrilla-
tion incidence was observed in acute myocardial infarction
patients with an SK value <3.9 mmol/L,22 indicating that
hypokalemia may cause fatal arrhythmia and should be
corrected as soon as possible in clinical practice. Further-
more, it has been reported that potassium depletion in dogs
was associated with impairment of left ventricular (LV)
mechanical function.28,29 Srivastava and Young28 later
Table 3 Multivariate-adjusted HR for all-cause and CVD mortalities by serum potassium status for Elderly NAHSIT, VRH study,
and combined analysis.
Serum potassium Elderly NAHSITa VRH studya Combined analysisb
HR (95% CI) p HR (95% CI) p HR (95% CI) p
All-cause mortality
Low SKc 2.4 (1.5e3.7) <0.001 1.0 (0.4e2.5) 0.975 1.8 (1.3e2.7) 0.003
Low-normal SKc 1.2 (0.9e1.6) 0.150 1.4 (1.0e2.2) 0.076 1.3 (1.0, 1.6) 0.034
Normal SKc 1 1 1
High-normal SKc 1.1 (0.9e1.4) 0.549 1.1 (0.9e1.4) 0.340 1.1 (1.0e1.4) 0.126
CVD mortalityd
Low SKc 2.3 (1.0e5.4) 0.051 0.7 (0.1e5.0) 0.682 1.6 (0.7e3.4) 0.261
Low-normal SKc 1.6 (1.0e2.6) 0.033 1.5 (0.7e3.4) 0.325 1.6 (1.1e2.3) 0.025
Normal SKc 1 1 1
High-normal SKc 1.2 (0.8e1.9) 0.339 1.3 (0.8e2.1) 0.301 1.3 (1.0e1.8) 0.082
CIZ confidence interval; CVDZ cardiovascular disease; HDL-CZ high-density lipoprotein cholesterol; HFZ heart failure; HRZ hazard
risk; ICD-9 Z International Classification of Diseases, 9th revision; IHD Z ischemic heart disease; LDL-C Z low-density lipoprotein
cholesterol; NAHSIT Z Elderly Nutrition and Health Survey in Taiwan; SK Z serum potassium; VRH Z veteran retirement home.
a In VRH study, adjusted factors were age, body mass index, serum LDL-C, HDL-C, cholesterol, triglyceride, glucose, uric acid,
creatinine and sodium; systolic blood pressure, diastolic blood pressure, the prevalence of hypertension, diabetes, cardiac disease,
kidney dysfunction, and stroke. In Elderly NAHSIT, sex was additionally adjusted.
b Combined analysis included data from the VRH study and the Elderly NAHSIT. In this analysis, the study effect was adjusted.
c Low SK (2.8e3.4 mmol/L), low-normal SK (3.5e3.8 mmol/L), normal SK (3.9e4.4 mmol/L), and high-normal SK (4.5e5.6 mmol/L).
d CVD death certificates with ICD-9 codes of 250 (diabetes), 401e405 (hypertension), 410e414 (IHD), 428 (HF), or 430e438 (stroke).
Low-normal serum K and mortality in elderly 523proved the correlation between LV function and potassium
concentration in humans, showing that moderate potassium
depletion impaired the active relaxation of LV. In addition
to the impaired LV function and cardiac arrhythmia caused
by hypokalemia, experimental studies in animals showed
that keeping a high normal potassium level may have a
direct beneficial effect on the cardiovascular system, which
may be independent of, but additive to, its effect on blood
pressure.30 Furthermore, experimental animal studies
demonstrated that potassium has inhibitory effects on free
radical formation, vascular smooth muscle proliferation,
and arterial thrombosis.31 Additionally, potassium supple-
ment may reduce macrophage adherence to the vascular
wall and thereby contribute to the reduction of vascular
lesions,32 indicating that potassium may have a beneficial
effect in reducing cardiovascular events. Therefore, one
may conclude that accumulating lines of evidence have
indicated that an adequate potassium status can reduce
blood pressure, risk of stroke, ventricular arrhythmia, and
QT prolongation.25
Although the association between hypokalemia and
increased cardiovascular death has been observed in pa-
tients with preexisting CVD and renal failure,21e24 less is
known about the prognostic value of SK at the ranges
commonly encountered, especially for the elderly in the
community. Our study demonstrated that low-normal SK
concentration was associated with higher cardiovascular
and all-cause mortality rates than the mid-normal potas-
sium level among community-dwelling elderly people.
Contrary to what has been reported previously,21 a good
proportion of our study participants have normal serum
creatinine or eGFR values, indicating that maintaining an SK
level higher than the lower bound of the usual normal range
is also important for outpatient care. Walsh et al8 have
reported in one community-based cohort that the SK levelwas not associated with future risk of cardiovascular death
in individuals free of CVD and not taking medications
affecting potassium homeostasis. In their study, the par-
ticipants were much younger (40e59 years old) than ours
(mean age, 72.8  5.9 years). Because a low SK level was
reported to be associated with some important risk factors
for CVD mortality, such as old age, more comorbidities,
malnutrition, and lower BMI,10 differences in baseline
characteristics may explain the different results between
these two observations. Observational studies of inverse
association between potassium-rich diet and the occur-
rence of CVD have been reported decades ago by Khaw and
Barrett-Connor,11 who recorded a 10-mmol increase in daily
potassium intake associated with a 40% reduction in the risk
of stroke-associated mortality (p < 0.001). A recent study
associating 24-hour urinary potassium excreted with car-
diovascular events, using data from 101,945 persons in 17
countries, showed that higher K excretion was associated
with a lower risk of death and cardiovascular events.33 In
addition, our group had previously shown that elderly men
provided with potassium-enriched salt diet could live
0.3e0.9 year longer, had lower CVD mortality, and spent
less on medical expenses for inpatient care than controls.12
Taken together, managing a low-normal potassium level is
critical for reducing all-cause and cardiovascular mortality
in daily care practice for the elderly. Nonetheless, it is best
to provide potassium through a balanced diet approach,
which may ensure a reasonable dietary potassium range. In
addition, the patient’s SK should be carefully monitored.
Our study has several limitations. We measured SK con-
centration at a single point in time. Because of this, we
could not account for changes in SK levels over time.
However, we believe that with multiple SK measurements
to increase precision, the observation may become more
apparent. In addition, the sample sizes of both studies are
Table 4 Prospective studies on serum potassium level and mortality.
Authors, year Study name Age (y) Studied
population
n Years of
follow-up (y)
Serum potassium
level (mmol/L)
All-cause mortality CVD mortality
HR (95% CI) HR (95% CI)
Walsh et al, 20028 The Framingham
Heart Study
43  10 General 3151 16 3.5e4.0 1.1 (0.6e2.1) 0.8 (0.4e1.5)
4.1e5.1 (Ref) 1 1
5.2e6.2 0.9 (0.6e1.2) 1.0 (0.7e1.3)
Fang et al, 200015 NHANES I Epidemiological
Follow-up Study
46.6  13.9 General 2836 18 2.7e3.7 d 1.0 (0.6e1.5)
3.8e4.4 (Ref) d 1
4.5e5.4 d 1.5 (1.0e2.3)
Lai et al, 2015
(this study)
Elderly NAHSIT & VRH 72.8  5.9 General 2065 8 2.8e3.4 1.8 (1.2e2.7) 1.6 (0.7e3.4)
3.5e3.8 1.3 (1.0e1.6) 1.6 (1.1e2.3)
3.9e4.4 (Ref) 1 1
4.5e5.6 1.1 (1.0e1.4) 1.3 (1.0e1.8)
Wannamethee
et al, 19979
The British Regional
Heart Study
40e59 CVD (treated
for hypertension)
7735 11.5 2.8e3.9 (Ref) 1 1
4.0e4.2 1.2 (0.9e1.60) 1.5 (1.0e2.2)
4.3e4.5 1.2 (1.0e1.6) 1.4 (1.0e1.9)
4.6e4.8 1.4 (1.0e1.8) 1.3 (0.9e2.0)
4.9e5.1 1.2 (0.8e1.4) 1.4 (0.8e2.4)
5.2e6.0 1.7 (1.2e2.8) 1.5 (0.8e2.8)
Korgaonkar
et al, 201018
The Renal Research
Institute CKD study
60.5  15.4 CKD 820 0e7
(mean: 2.6)
2.5e4.0 1.9 (1.0e3.6) d
4.1e5.4 (Ref) 1 d
5.5e7.0 1.8 (0.8e4.2) d
Ahmed et al, 200716 DIG trial (propensity
matched)
63  11 HF 2374 3.1 3.5e3.9 1.3 (1.1e1.5) 1.3 (1.1, 1.5)
4.0e5.5 (Ref) 1 1
Bowling et al, 201017 DIG trial (propensity
matched)
68  10 HF with CKD 1044 4.8 y 3.5e3.9 1.6 (1.3e2.0) 1.7 (1.3e2.1)
4.0e4.9 (Ref) 1 1
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Low-normal serum K and mortality in elderly 525not large; therefore, we had limited statistical power to
study the possible moderate association between mild hy-
pokalemia and other causes of death. Further studies with
larger sample sizes are warranted to clarify the association
between SK concentration and mortality in the elderly.
Conclusion
Community-dwelling elders with low-normal SK
(3.5e3.8 mmol/L) had increased all-cause and cardiovas-
cular mortality rates compared to those with mid-normal
values (3.9e4.4 mmol/L) in this 8-year follow-up study. The
low-normal SK status may serve as a prognostic factor of
poor survival in elderly outpatient care.
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